Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Atazanavir · Reyataz, ATV

Small molecule · Inhibitor of HIV-1 protease · developed by Bristol Myers Squibb

Approved FDA, Jun 2003

1 Registered trials

What is Atazanavir?

Atazanavir is an HIV-1 protease inhibitor used in combination with other antiretroviral agents to treat HIV-1 infection in adults and pediatric patients 3 months and older weighing at least 5 kg.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Reyataz, ATV
Drug type: Small molecule
Targets: HIV-1 protease
Mechanism: Inhibitor of HIV-1 protease
Therapy area: Infectious disease
Developer: Bristol Myers Squibb
In trials of: GILD
FDA status: Approved as Reyataz (June 20, 2003), NDA021567 · FDA label

✅ FDA-approved uses

HIV-1 infection

From the indications section of the FDA label (version of Dec 5, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06337032	Phase 4	HIV-1-infection	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HIV-1-infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z